Business Wire

Robert J. Giuffra, Jr. and Scott Miller Become Co-Chairs of Sullivan & Cromwell LLP

3.1.2022 17:46:00 EET | Business Wire | Press release

Share

Sullivan & Cromwell LLP announced today that Robert J. Giuffra, Jr. and Scott Miller have become Co-Chairs of the firm, effective January 1, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005204/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Robert Giuffra and Scott Miller become Co-Chairs of Sullivan & Cromwell LLP. (Photo: Sullivan & Cromwell LLP)

Mr. Giuffra and Mr. Miller have served as Vice Chairs of the firm since January 2021. They succeed Joseph C. Shenker, the firm’s Chair since 2010, who will continue to serve on the firm’s Management Committee as Senior Chair in addition to continuing with his active client practice.

“Since the days of our founders, Sullivan & Cromwell has an unwavering commitment to our clients, our people and our communities,” said Mr. Shenker. “Bob and Scott exemplify these qualities, long ago establishing themselves as trusted counselors whose complementary strengths in litigation and corporate law reflect the broad scope of work we do for our clients around the world.”

“Our firm’s international practice and ability to deliver integrated client service through our network of 13 offices across four continents are critical to our success,” said Mr. Miller. “More than half of our firm’s clients are headquartered outside the United States, and Bob and I have each spent our careers handling our clients’ most complex cross-border matters. As the world becomes even more integrated and the issues clients face become more complex, we expect our global practice to be a driver of our firm’s continued success.”

“I am honored to work with Scott and our partners to build on our firm’s strong culture of excellence, innovation and commitment to our clients and each other,” said Mr. Giuffra. “For 143 years, our model has been tried and true: to recruit and train the best lawyers to work together to help our clients solve their most critical challenges and capture their highest value opportunities.”

Mr. Giuffra, a nationally prominent litigator, joined S&C in 1989 after serving as a law clerk to Chief Justice William Rehnquist of the U.S. Supreme Court and Judge Ralph Winter of the U.S. Court of Appeals for the Second Circuit. Based in New York, he has been a member of Sullivan & Cromwell’s Management Committee since 2007. A fellow of the American College of Trial Lawyers and International Academy of Trial Lawyers, he has successfully represented the firm’s clients in multi-billion dollar trials, litigations and government investigations. He has played a significant role in navigating some of the biggest corporate crises of the past 20 years, including the bankruptcy of Enron, the accounting frauds at Computer Associates and HealthSouth Corporation, the financial crisis, and the Volkswagen diesel emissions crisis for which he served as the carmaker’s national coordinating counsel. His current clients include Allianz, Goldman Sachs, Stellantis, UBS and Volkswagen. He has represented corporate boards and directors, CEOs, senior public officials, prominent families, law firms and professional sports teams.

Mr. Miller, a premier corporate counselor, joined S&C in 1986 after serving as a law clerk to Judge William A. Norris of the U.S. Court of Appeals for the Ninth Circuit. He routinely handles multi-billion dollar M&A, capital markets and other strategic transactions, internal and government investigations and other corporate crises. Now based in New York, he has been a member of the Firm’s Management Committee since 2014 and coordinates our U.S. and European corporate practices. He has worked on M&A and securities transactions in more than 20 countries, including the first privatization in Italy and the first German LBO. He represented Fiat Chrysler in its $60 billion merger with Peugeot, which transformed the global auto industry through the creation of Stellantis. Earlier, he represented Fiat in connection with its 2009 rescue of Chrysler, Ferrari in its 2015 IPO, and Alcan in fighting off a hostile takeover offer from Alcoa and in its $46 billion acquisition by Rio Tinto. He has represented DISH Network for two decades and recently in a series of transactions that helped it form and fund its nationwide wireless communications network. He has also recently been in the forefront of the SPAC market, representing among others DraftKings in its de-SPAC listing and other acquisitions and financings to create one of the world’s largest digital sports entertainment and gaming companies and Ermenegildo Zegna Group in its merger with a SPAC sponsored by Investindustrial through which Zegna became a NYSE-listed company, with an initial market capitalization in excess of $3 billion.

Mr. Giuffra is a graduate of Princeton University and Yale Law School. He has served as Chief Counsel of the U.S. Senate Banking Committee and as President of the Federal Bar Council. He is a member of New York’s Permanent Commission on Access to Justice and the Standing Committee on Rules of Practice and Procedure of the U.S. Courts. He is chair of the American Swiss Foundation.

Mr. Miller is a graduate of Arizona State University and Columbia Law School. He was managing partner of Sullivan & Cromwell’s Palo Alto office and has been resident in the firm’s London and Los Angeles offices. He is a trustee of the United States Council for International Business.

About Sullivan & Cromwell LLP

Sullivan & Cromwell LLP is a global law firm that advises on significant litigation, corporate investigations and complex regulatory, major domestic and cross-border M&A, finance, corporate and restructuring transactions, tax and estate planning matters. Founded in 1879, Sullivan & Cromwell has approximately 900 lawyers located in offices in New York, Washington, Los Angeles, Palo Alto, London, Frankfurt, Paris, Brussels, Hong Kong, Beijing, Tokyo, Melbourne and Sydney.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Matthew J. Corrigan
corriganm@sullcrom.com
+1 (212) 558-4906

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye